Prostate Cancer

Interim data from a phase 2 study indicate that neoadjuvant hormone therapy may reduce tumor volume in men with high-risk prostate cancer planning to undergo radical prostatectomy.

Thomas A. Hope, MD, discusses the positive findings from a phase 3 imaging study, which utilized 68Ga-PSMA-11 PET in the detection of pelvic nodal metastasis in men with intermediate- or high-risk prostate cancer.

Neal D. Shore, discusses the potential utility of relugolix in patients with advanced prostate cancer.

Thomas Hope, MD, discusses the clinical impact of using 68Ga-PSMA-11 PET to detect pelvic nodal metastasis in men with intermediate- or high-risk prostate cancer.

Liquid biopsy with circulating tumor DNA could help alleviate some of the challenges of tissue biopsy in prostate cancer, and in doing so, lead to a better precision medicine model in the field.

​Neal D. Shore, MD, FACS, discusses the safety profiles of relugolix and leuprolide in advanced prostate cancer.

Exelixis, Inc. has launched the phase 3 CONTACT-02 trial examining cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer who have received prior treatment with 1 novel hormonal therapy.

Huma Q. Rana, MD, MPH, discusses the prevalence of pathogenic variants in patients with prostate cancer enrolled on the ProGen study.

Michael J. Morris, MD, discusses the combination of atezolizumab and radium-223 dichloride, which did not demonstrate a clinical benefit in patients with metastatic castration-resistant prostate cancer.

Alexandra Sokolova, MD, discusses the implementation of systematic germline genetic testing in veterans with metastatic prostate cancer appeared to be feasible due to high consent rates, especially with direct oncologist involvement.

Fred Saad, MD, FRCS, discusses unanswered questions from the randomized phase 3 SPARTAN trial in nonmetastatic castration-resistant prostate cancer.

Alexandra Sokolova, MD, discusses the rationale for ​systematic germline testing in patients with metastatic prostate cancer.

Neeraj Agarwal, MD, discusses the results from the cohort 6 analysis of the COSMIC-021 trial in patients with metastatic castration-resistant prostate cancer​.

The United Kingdom’s National Institute for Health and Care Excellence has chosen to not recommend abiraterone acetate with prednisone/prednisolone plus androgen deprivation therapy as a treatment for patients with newly diagnosed, high-risk hormone-sensitive metastatic prostate cancer.

Kim Chi, MD, discusses the utility of liquid biopsy in prostate cancer.

William K. Kelly, DO, discusses the next steps with the combination of radium-223 dichloride and niraparib in metastatic castration-resistant prostate cancer.

Fred Saad, MD, FRCS, discusses unique characteristics of apalutamide compared with other antiandrogen agents in nonmetastatic castration-resistant prostate cancer.

Alexandra Sokolova, MD, discusses the challenges of germline testing in patients with metastatic prostate cancer. 

Huma Q. Rana, MD, MPH, discusses germline genetic testing in men with advanced prostate cancer.

Fred Saad, MD, FRCS, discusses the safety profile of apalutamide in nonmetastatic castration-resistant prostate cancer.

Alexandra Sokolova, MD, discusses the systematic implementation of a germline testing protocol for patients with metastatic prostate cancer.

The FDA has granted a priority review designation to a new drug application for relugolix as a treatment for patients with advanced prostate cancer.

​Neal D. Shore, MD, FACS, discusses the rationale for conducting the phase 3 HERO trial in advanced prostate cancer.

The addition of apalutamide to androgen deprivation therapy, significantly improved overall survival and metastasis-free survival in patients with nonmetastatic castration-resistant prostate cancer.

Alexandra Sokolova, MD, discusses the rationale for systematic implementation of germline testing for patients with metastatic prostate cancer.

Michael J. Morris, MD, discusses factors to consider when deciding among PET tracers in prostate cancer.

William K. Kelly, DO, discusses the design of a phase 1B dose-finding trial that evaluated the combination of radium-223 dichloride and niraparib in metastatic castration-resistant prostate cancer.